Regeneron Pharmaceuticals’ (REGN) Underperform Rating Reiterated at Bank of America

Bank of America reaffirmed their underperform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report issued on Tuesday morning, Marketbeat Ratings reports. The brokerage currently has a $565.00 price target on the biopharmaceutical company’s stock.

REGN has been the subject of several other research reports. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Wells Fargo & Company lowered their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. Truist Financial cut their target price on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research note on Friday, November 1st. BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Finally, Leerink Partners reiterated a “market perform” rating and set a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,099.90.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $740.97 on Tuesday. The business has a 50 day moving average price of $860.87 and a two-hundred day moving average price of $1,007.41. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market capitalization of $81.43 billion, a price-to-earnings ratio of 19.13, a price-to-earnings-growth ratio of 3.00 and a beta of 0.08. Regeneron Pharmaceuticals has a 1-year low of $735.95 and a 1-year high of $1,211.20.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Brown Lisle Cummings Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 18.2% during the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 10 shares in the last quarter. Sachetta LLC raised its stake in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares in the last quarter. Adirondack Trust Co. lifted its holdings in shares of Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after buying an additional 10 shares during the last quarter. UMB Bank n.a. grew its stake in shares of Regeneron Pharmaceuticals by 1.1% in the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after buying an additional 10 shares in the last quarter. Finally, Western Financial Corp CA grew its stake in shares of Regeneron Pharmaceuticals by 0.7% in the 2nd quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company’s stock valued at $1,912,000 after buying an additional 12 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.